论文部分内容阅读
为探讨心康饮口服液防治经皮冠状动脉成形术 (PTCA)后再狭窄的疗效及其作用机理 ,临床选择PTCA患者 6 0例 ,随机分治疗组(中药心康饮 )对照组 (西药常规治疗 )各 30例 ,疗程 3个月 ;另建立家兔实验性动脉狭窄模型 ,观察心康饮对家兔实验性动脉狭窄及其胸主动脉平滑肌细胞增生的影响。结果 :治疗组与对照组比较 ,在改善临床症状 ,减少心绞痛发作及心肌缺血 (EKG)改善率方面有显著差异 (P <0 .0 5 ) ;实验研究结果显示 ,心康饮可明显降低家兔血清胆固醇、甘油三酯水平 (P <0 .0 1) ;改善血小板聚集率 (P <0 .0 5 ) ,镜下观察可明显减轻家兔骼动脉狭窄 (P <0 .0 1) ,并可抑制家兔胸主动脉平滑肌细胞的增生。提示心康饮口服液对PTCA后再狭窄有一定的防治作用
To investigate the therapeutic effect of Xinkangyin Oral Liquid on prevention of restenosis after percutaneous transluminal coronary angioplasty (PTCA) and its mechanism of action, clinically selected 60 patients with PTCA were randomized to the treatment group (Xinkangyin) control group (Western medicine routine Thirty patients in each group were treated for 3 months. Another experimental animal model of arterial stenosis was established to observe the effects of Xinkangyin on experimental arterial stenosis and smooth muscle cell proliferation of thoracic aorta in rabbits. RESULTS: Compared with the control group, the treatment group had significant differences in improving clinical symptoms and reducing the incidence of angina pectoris and myocardial ischemia (EKG) (P < 0.05). Experimental results show that Xinkangyin can be significantly reduced. Serum cholesterol and triglyceride levels in rabbits (P < 0.01), platelet aggregation rate (P <0.05), microscopic observation can significantly reduce arterial stenosis in rabbits (P <0. 01). , And can inhibit the proliferation of rabbit thoracic aorta smooth muscle cells. Tips Xinkangyin Oral Liquid has a preventive and therapeutic effect on restenosis after PTCA